Introduction
Most castration-resistant prostate cancer (CRPC) continues to be dependent on transcriptionally active androgen receptor (AR). Recently, powerful agents in the arsenal of hormone therapies for advanced prostate cancer, such as abiraterone and enzalutamide, have been approved based upon 5-to 6-month improvements in overall survival. Approximately 20%-40% of patients with metastatic CRPC have primary resistance to enzalutamide or abiraterone (1) (2) (3) (4) , and patients that were originally responsive will all eventually fail. One mechanism of resistance to current hormone therapies is the presence of constitutively active splice variants of AR (AR-Vs) (5) (6) (7) .
Full-length AR is a ligand-activated transcription factor with distinct functional domains that include the C-terminal ligand-binding domain (LBD), to which androgens and antiandrogens bind; the hinge region, which contains a nuclear translocation sequence; the DNA-binding domain (DBD), which binds to androgen response elements (AREs) in the enhancers/promoters of target genes; and the N-terminal domain (NTD), which contains activation function-1 (AF-1) that is essential for AR transcriptional activity (8) (9) (10) .
All current hormone therapies target the AR LBD either directly with antiandrogens or indirectly by reducing levels of androgen that bind to AR LBD. Constitutively active AR-Vs, such as V7 and V567es, lack a full LBD and are nonresponsive to both androgen and therapies targeting AR LBD (11, 12) . Abiraterone and enzalutamide increase expression of V7 in prostate cancer cells and xenografts (7, 12, 13) . AR-Vs mediate a growth advantage for prostate cancer in androgen-deprived conditions (11, 14) and are detected in CRPC tissues (11, 14, 15) . Of the more than 20 AR-Vs discovered (16, 17) , V7 and V567es are clinically relevant, with levels of expression correlated to poor survival and CRPC (16) . Detection of V7 in circulating tumor cells (CTCs) of prostate cancer patients is prognostic of resistance to enzalutamide and abiraterone (5) , whereas V7-positive patients respond to taxanes (18) . Thus, the ability to determine AR-Vs status of CRPC patients is vital to their clinical management to prevent patients from receiving futile, high-cost treatments and therapies (e.g., enzalutamide, $7,450/month and abiraterone $5,000/month).
Constitutively active splice variants of androgen receptor (AR-Vs) lacking ligand-binding domain (LBD) are a mechanism of resistance to androgen receptor LBD-targeted (AR LBD-targeted) therapies for metastatic castration-resistant prostate cancer (CRPC). There is a strong unmet clinical need to identify prostate cancer patients with AR-V-positive lesions to determine whether they will benefit from further AR LBD-targeting therapies or should receive taxanes or investigational drugs like EPI-506 or galeterone. Both EPI-506 (NCT02606123) and galeterone (NCT02438007) are in clinical trials and are proposed to have efficacy against lesions that are positive for AR-Vs. AR activation function-1 (AF-1) is common to the N-terminal domains of fulllength AR and AR-Vs. Here, we provide proof of concept for developing imaging compounds that directly bind AR AF-1 to detect both AR-Vs and full-length AR. 
Results

I-EPI-002
. EPI-001 and its analogs bind AF-1 (22) that is common to both full-length AR and AR-Vs. For an imaging agent to be successful, it must have excellent binding affinity for its target. The most potent stereoisomer of the EPI-001 mixture is EPI-002 (23), which was employed as the starting scaffold for synthesis of cold 15-IodoEPI002 (called I-EPI-002) ( Figure 1 and described in the Supplemental Experimental Procedures; supplemental material available online with this article; doi:10.1172/jci.insight.87850DS1).
Iodination improves the potency of EPI-002 in functional assays. Iodination of EPI-002 (I-EPI-002) could potentially alter many of the properties of the parent compound EPI-002, such as potency, biological activity, and off-target effects. Since excellent binding affinity is critical for an imaging agent to be successful, we first tested whether iodination of EPI-002 improved or diminished its potency using well-established cell-based functional assays. Dose response curves using the AR-driven prostate-specific antigen (PSA) (6.1 kb) luciferase reporter were used to calculate IC 50 values for inhibition of endogenous AR transcriptional activity by I-EPI-002 compared with EPI-002 in LNCaP cells. I-EPI-002 had an IC 50 of 1.17 ± 0.22 μM for inhibition of AR transcriptional activity (Figure 2A ). This is comparable to that reported for the antiandrogen enzalutamide, which is considered to have strong affinity for the AR. At 1 μM, enzalutamide caused 67% inhibition of ARE(4x) luciferase activity (25) . I-EPI-002 had an IC 50 of approximately 1 μM to block AR-driven proliferation of LNCaP cells in response to androgen ( Figure 2B ). I-EPI-002 had no effect on proliferation or viability of PC3 and DU145 human prostate cancer cells that do not express functional AR at up to 10 times the IC 50 required to reduce AR-dependent proliferation, thereby supporting its specificity for AR. I-EPI-002 is 10 times more potent than EPI-002, which has IC 50 in the range of 10 μM for these cell-based assays (22, 23) . Together, these data support that I-EPI-002 has improved potency compared with EPI-002 and are consistent with saturation transfer difference-NMR data, showing strong interaction of the bisphenyl rings of EPI with Tau-5 of AR AF-1 (24) .
I-EPI-002 maintains specificity for AR. Imaging agents are administered at microdoses and thus must be highly specific for their targets. Therefore, we next examined whether I-EPI-002 would potentially interact with the proteins most highly related to AR in the human proteome, which are the other steroid receptors, progesterone receptor (PR), glucocorticoid receptor (GR), and estrogen receptor (ER). In addition to high sequence identity in the LBD and DBD of this class of receptors, they also interact with many of the same proteins, such as CBP (CREB-binding protein) and SRC1-3. A sensitive method to determine if I-EPI-002 interacts with any of these other receptors is to measure their transcriptional activities. Therefore, reporter gene assays were used to determine if I-EPI-002 would inhibit PR, GR, or ER transcriptional activities. Cells were cotransfected with expression plasmids for full-length human PRβ, GR, ERα, and their respective reporters and then treated with ethanol vehicle, 4-pregnene-3,20 dione (progesterone) (PRβ), dexamethasone (GR), or estradiol (E2) (ERα). At a concentration of ~2 μM, I-EPI-002 inhibited AR transcriptional activity to similar levels (75%) to that achieved with 25 μM EPI-002 ( Figure 2C ). Importantly, I-EPI-002 did not inhibit the transcriptional activities of PR, GR, or ER in response to their cognate ligands ( Figure  2D and Supplemental Figure 1, A and B) . These data provide evidence that I-EPI-002 does not have general effects on transcription or translation because it did not inhibit induction of PRE (progesterone response element), GRE (glucocorticoid response element), or ERE (estrogen response element) luciferase reporters in response to ligand. Thus, I-EPI-002 appears to maintain specificity for AR.
I-EPI-002 does not interfere with ligand binding. EPI analogs bind specifically to AR AF-1 without being affected by, or interfering with, ligand binding to AR LBD (22, 23) . This is an important attribute for an imaging agent for CRPC, because AR LBD may be occupied by antiandrogen or steroid/androgen. To test whether I-EPI-002 maintained this property and does not affect ligand binding to AR LBD, we employed the fluorescence polarization assay. This assay measures competition of a test compound for binding of fluoromone to recombinant AR LBD or other related steroid hormone receptor LBDs. R1881 and the antiandrogen enzalutamide both bound to the AR LBD to compete with the fluoromone as expected ( Figure 2E ). I-EPI-002 behaved consistently to EPI-002 and did not prevent ligand-binding to the LBDs of AR or any steroid hormone receptors tested (Supplemental Figure 1 , C-F). Consistent with these data, I-EPI-002 and EPI-002 maintained effective inhibition of AR transcriptional activity with increasing concentrations of androgen ( Figure 2F ), unlike enzalutamide, which markedly lost potency, as expected for a competitive antiandrogen. These data support that imaging with a molecular probe targeted to AR AF-1 should not be affected by an occupied AR LBD.
I-EPI-002 targets AR-Vs. Constitutively active AR-Vs that lack LBD are detected in clinical samples of CRPC, and levels of expression are correlated with poor prognosis and resistance to abiraterone and enzalutamide, which target the AR LBD (5, 11, 14, 16, 26, 27) . To ensure that the addition of the iodo to EPI-002 had no detrimental effect on its ability to interact with truncated AR-Vs, we performed direct comparison of I-EPI-002, EPI-002, and enzalutamide on solely endogenous full-length AR or endogenous full-length AR combined with V567es or V7. In the absence of V567es or V7, enzalutamide inhibited full-length AR induced by androgen, as measured with AR-driven probasin luciferase reporter ( Figure 3A , left). Consistent with previous studies, enzalutamide had no effect in blocking AR transcriptional activity, either in the presence or absence of androgen, when V567es or V7 was expressed ( Figure 3A , middle and right). I-EPI-002 showed good inhibition against full-length AR as well as mixed populations of full-length AR with variant V567es or V7 at concentrations 10 times lower than those of EPI-002. This suggests that I-EPI-002 interacts with the truncated AR variants, consistent with EPI-002, but with better potency. Western blot analysis using an antibody against the AR NTD confirmed the approximate 1:1 ratio of endogenous full-length AR to ectopic V567es or V7 in whole cell lysates of cells treated with I-EPI-002, EPI-002, and enzalutamide ( Figure 3B ). I-EPI-002 was next tested to examine if it had effects on AR-V-driven proliferation. LNCaP95 cells are enzalutamide resistant (12, 28) and increase proliferation in the absence of androgen by a mechanism driven by AR-Vs. I-EPI-002 (2 μM) decreased proliferation of LNCaP95 cells as well as EPI-002 (25 μM), whereas enzalutamide (5 μM) had no effect ( Figure 3C ). I-EPI-002 had an IC 50 of 6.89 ± 2.85 μM for inhibition of LNCaP95 cell proliferation ( Figure 3D ). Consistent with these data, cell cycle analysis revealed that EPI analogs caused G 0 / G 1 arrest. Approximately 25%-30% of cells treated with enzalutamide or DMSO vehicle were in S phase ( Figure 3E ). Whereas I-EPI-002 or EPI-002 decreased S phase cells by approximately 2-fold or more with a concomitant increase of cells in G 1 phase. Western blot analysis of cell cycle G 1 /S-related proteins revealed that EPI analogs decreased the expression of UBE2C (ubiquitin-conjugating enzyme E2C), an AR-V7-regulated protein; cyclinD3; and cyclin-dependent kinases (CDKs). EPI analogs increased protein expression of the CDK inhibitor p27kip1. Importantly, enzalutamide had no effect on the levels of expression of these proteins, which was consistent with these cells being resistant to enzalutamide ( Figure 3F ). Together, these data support that I-EPI-002 targets full-length AR and AR-Vs. , or I-EPI-002 (5 μM) for 48 hours (refer to full and uncut gel images in Supplemental Materials). I-EPI, I-EPI-002; EPI, EPI-002; ENZ, enzalutamide. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One-way ANOVA Dunnett's multiple comparison test was utilized.
and specifically to AR in the LNCaP95 cells ( Figure 4D ). There was no indication that 123 I-EPI-002 was a random alkylator, consistent with previous reports that EPI-001 and EPI-002 do not react with glutathione at physiological pH (23, 29) . These data support the specificity of I-EPI-002 were conducted in male castrated NOD/SCID mice that each carried both a LNCaP95 and a PC3 xenograft. The LNCaP95 cell line was selected as the target CRPC xenograft due to its high level of expression of endogenous full-length AR and AR-V7. PC3 was selected as the nontarget xenograft because it has very low/negligible protein levels of AR. Table 1 I-EPI-002 was detected in the large intestine. Generally, there was low uptake and fast washout from nonspecific tissues.
Accumulation of 123 I-EPI-002 in LNCaP95 tumors did not support that it was binding irreversibly in this or any other tissues (Table 1) . To date, covalent binding of EPI to AR NTD has only been shown in vitro and in closed systems over a long time (23, 24) . Binding of EPI-002 is proposed as a 2-step process: a quick reversible binding, followed by a very slow covalent binding (23, 24) . It may be plausible that the short t ½ of EPI in vivo (~3 hours) may result in negligible covalent binding because it is not around long enough for covalent binding to occur.
123 I-EPI-002 reached a maximum 2.2% ± 0.5% ID/g uptake in LNCaP95 tumors at 1 hour after injection. This was greater than the maximum achieved for 18 F-FDHT (0.432% ± 0.183% ID/g ± SEM) in the target tissue of ventral prostate in rodents at 1 hour after injection (30 for AR-rich tissue (LNCaP95) compared with AR-deficient tissues (PC3). LNCaP95 tumor to blood ratio was 3.58 ± 0.66 ( Figure 5A ), which was similar to the 3.5 ratio achieved with 18 F-FDHT, which is used clinically (31). LNCaP95 tumor-blood and tumor-muscle ratios were greater than that of PC3 for all time points examined. Blocking with excess cold EPI-002 (50 mg/kg body weight) caused a 74% decrease (P < 0.001) in 123 I-EPI-002 accumulation in the LNCaP95 xenograft ( Figure 5B ), suggesting that the uptake of 123 I-EPI-002 was AR mediated. This 74% drop in LNCaP95 tumors by blocking with excess cold EPI-002 was similar to the 70% drop achieved with testosterone to block 18 F-FDHT (31). Blocking with excess cold EPI-002 had no significant effect on levels of 123 I-EPI-002 uptake in blood, muscle, and PC3 xenograft ( Figure 5B ). These data suggest that the accumulation of 123 I-EPI-002 in LNCaP95 xenografts was specifically AR mediated.
Micro-SPECT/CT imaging of 123
I-EPI-002. On the basis of the results from the biodistribution study and ratios of target tissues to nontarget tissues that were at similar to those achieved with clinically employed 18 F-FDHT, a whole-body micro-SPECT/CT study was performed to evaluate the specific tumor-targeting ability of 123 I-EPI-002. To do this, male castrated NOD/SCID mice bearing both LNCaP95 and PC3 xenografts of approximately equal volumes were scanned using SPECT. Scanning at 2 hours after tail vein injection of 123 I-EPI-002, when the tumor-blood and tumor-muscle ratios were sufficiently high, provided SPECT images shown in Figure 5C . 123 I-EPI-002 distinguished LNCaP95 tumors from PC3 tumors, whereas the liver region had relatively higher uptake ( Figure 5C ; Unblock). The amount of radiopharmaceutical uptake seen in the liver, which was concurrent with the low amount of gastrointestinal uptake, was likely due to the lipophilic nature of 123 I-EPI-002 and was consistent with the in vivo biodistribution data. LNCaP95 tumor uptake was similar to the tumor uptake observed in the biodistribution study (1.09% ± 0.41% ID/g at 2 hours after injection, n = 3). In addition, the 123 I-EPI-002 tracer accumulation was absent from SPECT images when blocked with excess cold EPI-002 ( Figure 5C ; Block). Importantly, the thyroid uptake was approximately 2.31% ± 0.59% ID/g and was not altered by blocking with EPI-002 (2.32% ± 0.33% ID/g). These data suggest that 123 I-EPI-002 may not be metabolically stable and that the 123 I may fall off the compound to accumulate in the thyroid. Histological analysis showed that LNCaP95 xenografts have more necrotic centers than PC3 xenografts ( Figure 5D ). This suggests that poor vascularization and consequent central necrosis may prevent optimal access of 123 I-EPI-002 to AR in LNCaP95 tumors. Western blot analysis using an antibody against the AR NTD and V7 confirmed the expression of full-length AR and V7 in LNCaP95 xenografts, which were undetectable in PC3 xenografts ( Figure 5E ). These data support that 123 I-EPI-002 accumulation in the LNCaP95 tumor was specific to full-length AR and AR-Vs. Together, all of these data support the feasibility of developing molecular imaging agents directed to AR AF-1 to detect the AR and AR-Vs to improve the clinical management of prostate cancer.
Discussion
Bone scans are routinely used for metastatic CRPC but they do not provide insight about the cancer itself or whether the lesions are AR positive to aid in treatment selection. Although bone metastates are the predominate site of dissemination, approximately 20%-30% of metastatic CRPC patients have visceral metastases (32, 33) . If visceral metastases are positive for full-length AR, they could benefit from hormone therapies that target AR LBD, such as enzalutamide (34) . Even so, approximately one-third of CRPC patients will have intrinsic resistance, and eventually all patients will acquire resistance to enzalutamide or abiraterone (1-4) . The major mechanisms of resistance to these therapies include gain-of-function mutations in AR LBD and/or expression of constitutively active AR-Vs that lack LBD (5-7). An important clinical example is drawn from a report using CTCs from CRPC patients, which revealed that, upon initiating enzalutamide treatment, those patients with CTCs that express V7 have a lower PSA response rate, shorter PSA-progression-free survival, shorter clinical or radiographic progression-free survival, and reduced overall survival compared with patients that had CTCs that were V7 negative (5). Compared with taxanes, hormone therapies are the preferred therapeutic due to low toxicity. However, taxanes are more efficacious than AR LBD-targeting therapies in V7-positive CRPC patients (18) . Therefore, the ability to distinguish those patients that express AR-Vs that are resistant to AR LBD therapies would be a significant advance in the clinical management of CRPC.
To date, assays to detect AR-Vs are still in early developmental stages, with most focused upon detection of AR-Vs in CTCs. This is because biopsy of the multiple lesions that predominate in the bone of CRPC patients is not viable, making the comprehensive assessment of expression of AR-Vs in metastatic tissues unfeasible. Clinical application of measurement of expression of AR-Vs using CTCs has several caveats that include abilities to isolate or detect CTCs and the sensitivity of the assay to measure levels of AR-Vs. Thus, a noninvasive imaging approach that could robustly reveal the presence of full-length AR and AR-Vs in all metastatic lesions is of utmost importance to identify patients that may or may not benefit from further antiandrogen or androgen ablation therapies. The optimal qualities for a potentially useful imaging probe to provide a noninvasive approach to localize metastatic lesions that express full-length AR and AR-Vs are a high binding affinity to AR NTD and low nonspecific binding affinity. Here, we propose developing an analog of EPI-002 as an AR NTD-targeted molecular imaging probe to detect all AR species. The fact that AR protein is commonly overexpressed in CRPC tissues supports the application of AR NTD-based imaging agents. We show here that I-EPI-002 (a) has 10 times greater potency than EPI-002; (b) maintained specificity for AR; (c) bound to the target, AR AF-1, to yield loss of functional transcriptional activities as expected; and (d) most importantly, that in vivo 123 I-EPI-002 enabled specific visualization of xenografts that express full-length AR and AR-Vs. I-EPI-002 is potentially the first imaging agent that can directly detect both full-length AR and AR-Vs. Importantly, these data also support the specificity of EPI-002 for AR.
The addition of a substituent in EPI-002 chemical structure could alter the binding of the probe to AR directly or by conformational effects. Here, the addition of iodine to EPI-002 had favorable effects on blocking the transcriptional activity of AR NTD without losing its specificity. The fact that 123 I-EPI-002 binds the AR NTD and does not affect binding of ligand to AR LBD is an important attribute for an imaging agent for this indication and molecular target. This is because imaging agents are applied at microdoses and hence are highly susceptible to competing agents For most applications, it is predicted that patients failing enzalutamide or other antiandrogens may have an AR LBD occupied by the antiandrogen. Washout of enzalutamide takes approximately 5 half-lives (t ½ = 6-9 days) or more than 1 month. In addition, if there is steroid hormone breakthrough in castrated or abiraterone-treated patients, or a mutation in AR LBD making the receptor promiscuous to binding other steroid, AR LBD could be occupied by steroid. Under these clinical conditions, an imaging agent that binds to AR NTD would theoretically not be affected, contrary to 18 F-FDHT, which competes for binding to LBD and has been shown to have diminished uptake at the tumor site in the presence of testosterone (35) . The quality of competing for the AR LBD can, however, be beneficial, as in application of 18 F-FDHT as a pharmacodynamic marker to demonstrate the effects of agents targeting the full-length AR (1) . Most importantly, in order to distinguish full-length AR from AR-Vs, an imaging agent that binds to the AR NTD, such as 123 I-EPI-002, which detects full-length AR and AR-Vs, would be required to be used in combination with an imaging agent that only detects full-length AR, such as 18 F-FDHT. By using sequential imaging, a discordant distribution or discordant level of uptake between 18 F-FDHT and a radiolabeled AR NTD imaging agent would indicate the presence of AR-Vs. This experiment was beyond the scope of these proof-of-concept studies; but, in the future, this experiment can be carried out with improved analogs. Such improvements that are currently underway encompass synthesizing a metabolically more stable imaging agent to use in place of 123 I-EPI-002 and moving away from an iodocompound. However, 124 I-EPI-002 might be useful for PET imaging and an 125 I-EPI-002 might be useful as a Auger emitter for therapeutic applications. In the event that an AR NTD-targeted molecular imaging probe has appropriate uptake and biodistribution, it could be further developed as a targeted radiotherapeutic to deliver α-or β-emitting radionucleotides to lesions that express full-length AR and/or AR-Vs in patients with metastatic CRPC.
In conclusion, these studies suggest that an AR NTD-targeted molecular imaging probe has significant potential for monitoring treatment response; providing insight into the role of all AR species, including AR-Vs, in resistance mechanisms of CRPC; and may provide a means of targeted radiotherapy.
Methods
Cells, plasmids, transfections, and reporter assays. The synthetic androgen R1881 was purchased from Perkin-Elmer. EPI-002 was provided by NAEJA. Enzalutamide was purchased from Omega Chem. Progesterone (4-pregnene-3,20-dione) was obtained from Steraloids Inc. Dexamethasone and HEPES were obtained from Sigma-Aldrich. LNCaP, PC3, and DU145 cell lines as well as PSA(6.1 kb) luciferase, probasin luciferase, PRE luciferase, GRE luciferase, ERE luciferase, AR-V7 and AR-V567es plasmids, and transfection of cells have been described previously (22, 23, 26, 29) . LNCaP cells were obtained from Leland Chung (Cedars-Sinai Medical Center, Los Angeles, California, USA) in September 1993. DU145 cells were from Victor Ling (British Colombia Cancer Agency, Integrative Oncology) in October 1998. LNCaP95, an androgen-independent cell line that expresses full-length AR and AR-V7, was provided by Stephen R. Plymate (University of Washington, Seattle, Washington, USA) in February of 2012 and reported in previous studies (12, 14, 36, 37) . PC3 cells were purchased from ATCC. LNCaP95 cells were not authenticated in our laboratory but were regularly tested to ensure that they were mycoplasma free (VenorTMGeM Mycoplasma Detection kit, Sigma-Aldrich). LNCaP, PC3, and DU145 cells were authenticated by short tandem repeat analysis and tested to ensure that they were mycoplasma free by DDC Medical in September 2013. All cells used in the experiments were passaged in our laboratory for fewer than 3 months after resurrection.
General I-labeled compounds were performed on an Agilent HPLC System equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector (set at 220 nm), and a Bioscan NaI scintillation detector. The radiodetector was connected to a Bioscan B-FC-1000 Flow-count System, and the output from the Bioscan Flow-count system was fed into an Agilent 35900E Interface, which converted the analog signal to digital signal. The operation of the Agilent HPLC system was controlled using the Agilent ChemStation software. The HPLC columns used were a semipreparative column (Phenomenex Luna C18, 5 μ, 250 × 10 mm) and an analytical column (Phenomenex Luna C18, 5 μ, 250 × 4.6 mm). Radioactivity of 123 I-labeled compounds was measured using a Capintec CRC-25R/W dose calibrator. Details are available in the Supplemental Experimental Procedures.
Fluorescence polarization. Androgen, PR, ER, and GR PolarScreen Competitor Assay kits (Invitrogen) were used according to the manufacturer's protocol. Serial dilution was done for each small molecule, and solvent was compensated to ensure equal volume of DMSO and ethanol in each sample. Fluorescence polarization at excitation wavelength 470 nm and emission at 530 nm was measured in Greiner 384 black clear-bottomed plates using Infinite M1000 (TECAN).
Viability and proliferation assays. PC3 cells (2,000 cells/well), DU145 cells (2,000 cells/well), and LNCaP cells (5,000 cells/well) were plated in 96-well plates in respective media plus 0.5% FBS. The next day, PC3 and DU145 cells were treated with DMSO (vehicle control) and I-EPI-002 for 3 days, and LNCaP cells were pretreated with vehicle and I-EPI-002 for 1 hour before treatment with 0.1 nM R1881 for 4 days. Proliferation and cell viability was measured using alamarBlue Cell Viability Assay (Invitrogen) following the manufacturer's protocol.
For BrdU incorporation experiments, LNCaP95 cells (8,000 cells/well) were seeded in 96-well plates for 48 hours in RPMI with 10% charcoal stripped serum, which was changed to serum-free media 24 hours before treatment with 5 μM enzalutamide, 25 μM EPI-002, 2 μM I-EPI-002, or serial concentrations of I-EPI-002. BrdU incorporation was measured after 2 days using the BrdU ELISA kit (Roche Diagnostics) according to the manufacturer's protocol.
FACS analysis. LNCaP95 cells (75,000 cells/dish) were plated in 10-cm dishes and were treated with inhibitors under serum-free and phenol red-free conditions for 48 hours. Cells were pulse labeled with 10 μM BrdU for 2 hours and fixed in 70% ethanol. BrdU-labeled cells were probed with anti-BrdU-FITC antibody (BD Biosciences), and DNA was stained with 7-aminoactinomycin D (Sigma-Aldrich). Data were acquired using a FACS Calibur (BD Biosciences). Bivariate analysis was performed using FlowJo 7 software (Ashland).
Binding assays. The cell-free binding assay was performed with commercially available full-length AR recombinant protein or AR AF-1 recombinant protein that was expressed and purified as previously described (22, 38) , with additional purification by size exclusion chromatography. Binding reactions between EPI-002 or DMSO (vehicle control) and the recombinant AR AF-1 (amino acid residues 142-485) or fulllength AR were carried out by mixing 60 μM EPI-002 or DMSO with 10 μM AR AF-1 and 1 μM EPI-002 or DMSO with 0.35 μM full-length AR in equivalent amounts. Binding reaction was incubated at room temperature for 6 hours. 200 μCi of 123 I-EPI-002 was then mixed in each sample at room temperature for 16 hours prior to SDS-PAGE. Proteins were separated from free probes on 8% SDS-PAGE, and radioactivity was visualized using Fujifilm FLA-7000 image analyzer (GE Healthcare). The same gel was stained with Coomassie blue R-250. To examine binding to the endogenous AR, LNCaP95 cells (60,000 cells/well) were seeded in 12-well plates and serum starved for 24 hours before treating cells for 16 hours with DMSO or 25 μM EPI-002 and with 400 μCi of 123 I-EPI-002. Proteins were extracted from treated cells with RIPA buffer containing 50 mM tris (pH 8.0), 150 mM NaCl, 0.5% Na Deoxycholate, 1% NP-40, 0.1% SDS, and EDTAfree protease inhibitors.
123
I-EPI-proteins were separated by SDS-PAGE, and radioactivity was visualized using Fujifilm FLA-7000 image analyzer, and subjected to Western blot analysis using anti-AR antibody.
